APVO 414

Drug Profile

APVO 414

Alternative Names: Anti-PSMA-X-Anti-CD3-ADAPTIR molecule; APVO-414; ES 414; MOR 209 ES 414; MOR-209/ES-414

Latest Information Update: 04 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aptevo Therapeutics; Emergent BioSolutions
  • Developer Aptevo Therapeutics; MorphoSys
  • Class Antineoplastics; Bispecific antibodies; Proteins
  • Mechanism of Action CD3 antigen inhibitors; Cytotoxic T lymphocyte modulators; Glutamate carboxypeptidase II inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 31 Aug 2017 Aptevo Therapeutics and MorphoSys ends joint development and commercialisation agreement for MOR209 ES414 in Prostate cancer
  • 31 Aug 2017 Preliminary immunogenicity and adverse events data from a phase I trial in Prostate cancer released by Aptevo Therapeutics
  • 31 Mar 2017 MOR209 ES414 is available for licensing as of 31 Mar 2017. http://aptevotherapeutics.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top